业绩修复周期开启，双主线聚焦“创新药+AI医疗”

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Views - The report indicates that the performance recovery phase has begun, focusing on "innovative drugs + AI healthcare" as key investment themes [4][17] - The report highlights a structural market trend in the pharmaceutical sector, with a strong performance expected in Q2 2025 due to the gradual recovery of the healthcare market and increased consumer demand [4][17] Summary by Sections 1. Industry Overview - The pharmaceutical and biotechnology sector's return rate for the week of April 28 to April 30, 2025, was 0.49%, outperforming the CSI 300 by 0.93%, ranking 9th among 31 sub-industry indices [11] - In Q1 2025, 99% of pharmaceutical companies disclosed their earnings, with 33% showing growth in both revenue and net profit [13][14] 2. Market Performance and Valuation - The pharmaceutical and biotechnology industry index had a PE (TTM) of 26.43, which is below the historical average of 31.15 [20][21] - The industry has experienced a relative performance of 0.45% over the last month, ranking 11th among 31 sub-industry indices [26] 3. Key Investment Themes - Innovative Drugs: Expected catalysts include negotiations on medical insurance and the introduction of new drug categories. Recommended stocks include Innovent Biologics, BeiGene, and others [17] - AI Healthcare: The report anticipates rapid development in AI healthcare, with significant investments in AI drug development and diagnostics. Key companies to watch include CrystalGenomics and KingMed Diagnostics [17][5] 4. Recovery and Consumer Demand - The report notes strong expectations for consumer healthcare sectors, particularly in ophthalmology and dental care, driven by recent consumption stimulus policies [5][17] - Companies in the medical retail sector, such as Yifeng Pharmacy and Dazhong Pharmacy, are highlighted as potential beneficiaries of this recovery [5][17] 5. Operational Improvement - Companies showing operational improvements, such as WuXi AppTec and Kelun Pharmaceutical, are recommended for investment due to expected significant performance recovery [5][17]